This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Monday's Health Winners & Losers

BioMarin Pharmaceutical's (BMRN - Get Report) shares rose after Baird Research upgraded the stock to outperform from neutral with a price target of $18. The stock gained 8.6% to $15.45.

Isolagen (ILE) advanced after coverage of the stock was initiated by research firm Merriman Curhan Ford with a buy rating. Shares were up 2.6% to $3.54.

Adams Respiratory Therapeutics (ARXT) fell 3.9% to $35.16 after the company said it's suing Mutual Pharmaceuticals and United Research Laboratories for patent infringement.

Genzyme (GENZ) received European regulatory approval for its joint pain drug Synvisc for treating osteoarthritis of the ankle and shoulder. The new approvals were based on two European trials studying patients who received one or two injections of the drug. Shares dipped 1.1% to $66.71.

Genentech (DNA) and Biogen Idec (BIIB - Get Report) received two new regulatory approvals covering the blood cancer drug Rituxan.

The Food and Drug Administration cleared Rituxan to treat CD20-positive, B-cell non-Hodgkin's lymphoma in patients who haven't received any prior treatments for the disease, in combination with a chemotherapy regimen consisting of cyclophosphamide, vincristine and prednisolone. The drug may also be used to treat patients with low-grade non-Hodgkin's lymphoma whose disease has responded or stabilized after treatment with the chemo. Genentech rose 1.2% to $83.72, while Biogen fell 1% to $44.24.

Accentia Biopharmaceuticals (ABPI) and a group of its investors have signed a definitive four-year agreement for $25 million in exchangeable convertible debenture financing. Accentia's shares added 0.8% to $2.60.

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
ABPI $0.00 0.00%
BIIB $264.62 0.57%
BMRN $80.74 -1.70%
AAPL $93.24 -0.41%
FB $117.81 -0.21%


Chart of I:DJI
DOW 17,660.71 +9.45 0.05%
S&P 500 2,050.63 -0.49 -0.02%
NASDAQ 4,717.0940 -8.5450 -0.18%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs